Tag - Mustang Bio

Markets

HCW starts Mustang Bio at buy; PT $7

H.C. Wainwright initiated coverage of Mustang Bio (NASDAQ:MBIO) with a “buy” rating and $7 price target. The stock closed at $2.89 on Aug. 12. Analyst Joseph Pantginis writes that Mustang is developing multiple novel...

August 13, 2019

Developments

FDA clears Mustang Bio IND for CAR T cell therapy

Mustang Bio (NASDAQ:MBIO) reported that the FDA approved its IND application for MB-102 for the treatment of acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk...

August 6, 2019

Tag - Mustang Bio

HCW starts Mustang Bio at buy; PT $7

FDA clears Mustang Bio IND for CAR T cell therapy

General

More